Methods of synthetically producing formulating and using secretoglobins SCGB1A1 SCGB3A2 and SCGB3A1 are provided. Methods of using secretoglobins SCGB1A1 SCGB3A2 and SCGB3A1 as therapeutic agents to affect long term patient outcomes such as preventing severe respiratory exacerbations of underlying conditions that require medical intervention including hospitalization are provided. Methods of producing recombinant human secretoglobins analytical methods pharmaceutical compositions and methods of use to prevent the long term sequelae of acute and chronic respiratory conditions are provided.